2- Iminobiotin

Drug Profile

2- Iminobiotin

Alternative Names: 2-IB; 2-Iminobiotin; Neufix

Latest Information Update: 22 Sep 2016

Price : $50

At a glance

  • Originator Neurophyxia
  • Developer Neurophyxia; University Medical Center Utrecht
  • Class Imidazoles; Neuroprotectants; Pentanoic acids; Small molecules
  • Mechanism of Action Nitric oxide synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Asphyxia

Most Recent Events

  • 14 Sep 2016 Phase-II clinical trials in Asphyxia (In neonates) in Congo (IV) (EudraCT2015-003063-12)
  • 01 Apr 2015 Phase-II clinical trials in Asphyxia (In infants) in Netherlands (IV) (EudraCT2014-004265-25)
  • 20 Jul 2004 Preclinical trials in Asphyxia in Netherlands (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top